US FTC sues to block Illumina/Pacific Biosciences

The US Federal Trade Commission has issued an administrative complaint alleging that a merger in the DNA sequencing industry will maintain Illumina’s monopoly by eliminating a nascent competitive threat.


Get unlimited access to all Global Competition Review content